Bay City Capital Expands Team with the Addition of David Beier, JD

San Francisco, CA — Bay City Capital, a leading venture capital firm focused on early-stage to growth equity investments in the life sciences, today announced the addition of David Beier, JD as Managing Director. David served as a senior officer for nearly a decade in each of the two largest biotechnology firms, Genentech and Amgen. Most recently, David served as Senior Vice President of Global Government Affairs at Amgen, responsible for global government affairs, as well as corporate communications, and philanthropy.

“Today’s rapidly evolving healthcare industry provides tremendous opportunity for investment both in the United States and globally. David brings an extensive government affairs and public policy background, providing unique insights to our investment team,” said Fred Craves, Founder and Managing Director of Bay City Capital. “David will play an integral role in moving the firm forward through the next phase of global healthcare investing.”

During his Amgen tenure, David helped create and supervised the firm’s coverage, reimbursement, access, pricing, and healthcare economics activities globally. Earlier in his career, David was Chief Domestic Policy Advisor to Vice President Al Gore during the Clinton Administration. Mr. Beier has been a partner in a large international law firm as well as Counsel to the US House of Representatives Committee on the Judiciary. He is admitted to practice law in New York and the District of Columbia.

“Bay City Capital has a well deserved reputation of delivering value for its investors and its portfolio companies through a vibrant platform of scientific and business acumen. Those characteristics are what attracted me to the firm,” said David Beier.

About Bay City Capital
Bay City Capital is a life sciences venture capital firm investing in opportunities across the various life sciences sectors in companies at all stages of development. Established in 1997, the firm has managed eight venture capital funds representing over $1.6 billion in capital commitments.

Bay City Capital has invested in over 100 life sciences companies globally, including Epizyme, Epocrates, GenturaDx, Hyperion Therapeutics, Ion Torrent Systems, Lexicon, MAP Pharmaceuticals, Medarex, Nabsys, NextWave Pharmaceuticals, Oculex Pharmaceuticals, Pharmion, Reliant Pharmaceuticals, and Sunesis Pharmaceuticals.

For more information, visit

< Back to News & Events